Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

National Marrow Donor Program®/Be The Match® Implements Comcast Business Wavelength Services to Help Match Cancer Patients With Donors

Comcast Twin Cities

Comcast Business today announced that it is providing the National Marrow Donor Program® (NMDP)/Be The Match®, the leading global leader working to save lives through cellular therapy with a 10 Gbps optical wavelength service. The high-capacity, low-latency network solution will help Be The Match strengthen network performance, keeping its clients and employees connected, and in turn helping to ensure that transplant donors are connected to patients in need. Be The Match provides patients access to more than 39 million donors worldwide who step up to donate their marrow or blood stem cells. By connecting patients with donors and delivering life-saving cells to them, Be The Match provides cures to patients with life-threatening blood cancers and 75 blood diseases. The organization continues to lead the way in developing new cellular therapies, and in improving transplant accessibility and outcomes. Conducting this life-saving research while supporting and connecting patients to the resources they need requires a high-bandwidth, low-latency network connection. “Our network is becoming more critical, especially as we move to the cloud. If our systems aren’t available, people’s lives could be at stake,” said Robert Hanson, Vice President, Information Security, Infrastructure and Architecture, at Be The Match. “Comcast Business’ network performance has been seamless.” Comcast Business Wavelength Services deliver superior connectivity over a dense wave division multiplexing (DWDM) optical transport network with high levels of performance. Wavelength technology provides users with the ability to transport both Ethernet and non-Ethernet protocols. The point-to-point optical fiber network helps deliver data across several of Be The Match’s locations, including its headquarters in Minneapolis, its branch offices and its data center location. Since implementing Comcast Business’ services, Be The Match has been able to continue supporting patients across its various locations without concerns over network connectivity. Additionally, the reliable and fast network connections help position the organization for rising bandwidth demands and network growth, setting it up to serve its clients into the future. “To stay swift and competitive, businesses across industries continue to incorporate cloud and data center operations into their daily functions. With this will come the need for networking technology that can not only support the shifts in business today, but the continually rising bandwidth needs that the future demands,” said Wolfgang Lewis, Vice President for Comcast Business, Twin Cities Region. “Comcast Business is proud to support National Marrow Donor Program/Be The Match with its network services and do its part in making a difference in our communities.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About National Marrow Donor Program®(NMDP)/Be The Match® The National Marrow Donor Program®(NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With more than 30 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®(Center for International Blood and Marrow Transplant Research®)—a collaboration with Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care. Contact Details Comcast Jill Hornbacher Jill_Hornbacher@comcast.com Finn Partners Chloe Huard chloe.huard@finnpartners.com Company Website https://twincities.comcast.com/

April 19, 2022 08:00 AM Eastern Daylight Time

G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

G Medical Innovations Holdings

TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investor warrants to purchase up to an aggregate of 6,250,000 ordinary shares. The purchase price for one ordinary share and one warrant to purchase one ordinary share is $1.50. The warrants have an exercise price of $1.50 per ordinary share, will be immediately exercisable, and will expire five years from issuance. A.G.P./Alliance Global Partners is acting as the sole placement agent for offering. The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the offering for the repayment of existing debt and working capital purposes. The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions. The Company also has agreed that certain warrants to purchase an aggregate of 2,400,000 ordinary shares of the Company that were issued to the investor in February 2022 will be amended to have a reduced exercise price of $1.50 per ordinary share. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 30 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

April 18, 2022 07:00 AM Eastern Daylight Time

AmeriLife’s Senior Market Advisors Partners With Buffalo Health Advisors

AmeriLife

Senior Market Advisors (SMA), one of the fastest growing field marketing organizations (FMO) in the insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Buffalo Health Advisors, one of the top health insurance distributors in Tennessee that specializes in Medicare Advantage, Medicare Supplement and PDP solutions, as well as health insurance for the under-65 market. The partnership brings more than 450 field agents in Buffalo’s network under the SMA banner, while also expanding SMA’s geographical footprint in the southeast United States. Per the agreement, terms of the deal were not disclosed. “Buffalo Health Advisors is a dynamic and exciting force in our industry,” said Andy Watkins, vice president of sales and agency development, East region, for Senior Market Advisors. “Senior Market Advisors and AmeriLife are excited to start leveraging our multiple synergies to promote its overall growth and the betterment of our Medicare beneficiaries.” “Simply, Buffalo Health Advisors has always been about bringing the very best marketing strategies, business services and fun to our agent partners,” added Joshua Borders, owner and vice president of sales for Buffalo Health Advisors. “We’re very excited to partner with SMA and AmeriLife to unlock amazing new tools, technologies and relationships for our partners and clients. We’ve only just begun!” While Buffalo Health Advisors will continue to operate as a stand-alone organization in SMA’s downline, it will consolidate its office resources at SMA’s Nashville, Tennessee, headquarters. Likewise, Borders will continue to oversee Buffalo’s day-to-day operations, reporting to SMA’s Vice President of Corporate Operations Victoria Buckman. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 insurance agents and advisors, more than 50 marketing organizations, and 50 insurance agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About Senior Market Advisors Senior Market Advisors (SMA) has been people over profits since 2007, by hard work and a commitment to “doing right” by the consumer. We have certainly knocked on our fair share of doors. We know the grit and determination involved in becoming a career agent. And as a result, we have become one of the fastest growing FMOs, doubling our business each year for the past five years. For more information, visit us online at SeniorMarketAdvisors.com. Contact Details AmeriLife Communications Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Senior Market Advisors Communications Sarah Smith ssmith@seniormarketadvisors.com AmeriLife Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

April 14, 2022 02:00 PM Eastern Daylight Time

Industrial Defender Unveils New Standalone OT Vulnerability Management Solution, Immunity by ID™

Industrial Defender

Industrial Defender, the leader in operational technology (OT) security, today announced the launch of Immunity by ID™, a new cloud-based offering that helps industrial security teams turn their OT asset inventory information into a risk-based vulnerability management program. The product is offered as a standalone solution or as an add-on within the Industrial Defender platform. Using current OT hardware and software inventory information from an asset visibility tool, CMDB or spreadsheet, this vendor-agnostic solution generates a prioritized list of vulnerabilities based on asset criticality and risk level, along with applicable patching data, to help keep critical infrastructure secure in the face of global cybersecurity threats. Immunity by ID is up and running in a matter of days, allowing users to begin their vulnerability management program immediately, and simple, transparent pricing lets them easily scale a subscription as they mature. “With the looming threat of a global cyber war, critical infrastructure organizations of all sizes are looking for straightforward solutions that rapidly deliver actionable intelligence to help them protect their essential systems,” said Peter Lund, CTO at Industrial Defender. “We created this tool to help companies better utilize the asset information they already have that may be nothing more than a data dump right now. Unlike other OT vulnerability management offerings on the market, ours is powered by an anonymized cloud, so as soon as a vulnerability is published, you'll know whether a device is at risk without waiting for the next software update.” Industrial Defender will be offering a free 14-day trial of Immunity by ID to qualified users at North American and European critical infrastructure companies through the end of May to support their efforts to shore up cybersecurity defenses. For more information, visit https://www.industrialdefender.com/immunity-by-industrial-defender/. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

April 14, 2022 09:00 AM Eastern Daylight Time

PathPresenter Introduces ClinPx™ - A Clinical Enterprise Platform

PathPresenter

Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded from around the world – directly in Beaker. PathPresenter, the premier digital pathology platform for education and conferences with more than 40,000 users and 20+ institutional licenses, now presents to clinical users a best-in-class clinical enterprise platform, ClinPx. ClinPx is a custom, institution-branded, clinical enterprise platform that enables pathology consultations to be directly viewed and reported in your institution’s LIS through our proprietary backend HL7 messaging engine. It has inbuilt quality control (QC) ensuring whole slide images are of diagnostic quality and has the ability to integrate validated AI models into the scanner-agonistic viewer. ClinPx allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists as well as bidirectional communication channels for ordering stains and recuts. It also enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. This functionality brings the control and organization of the clinical workflow back to the end user. Our first pilot installation with The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) integrates ClinPx into Epic’s Beaker LIS, allowing pathologists at The Ohio State University to receive, view, and sign out cases uploaded from around the world directly in Beaker. “Our goal is to use ClinPix to augment OSU’s pathology clinical consultation capabilities globally. ClinPx has the ability to integrate with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate,” said Dr. Anil Parwani, vice chair of anatomic pathology at The Ohio State University College of Medicine. Rajendra Singh, co-founder of PathPresenter, added “ClinPX creates a solution to allow for the integration of digital pathology into existing workflows used by pathologists without disruption.” This platform is installed as a pilot project at The Ohio State University for potential expansion of its digital pathology consultation service. Dr. Parwani has no personal conflicts of interest to disclose. About PathPresenter PathPresenter is the world’s most widely used digital pathology platform, with a community of more than 40,000 users in 172 countries and 20+ institutional licenses. Our educational and conference module provides a seamless environment for pathologists, radiologists, clinicians, and life science researchers to use, share and collaborate with fellow clinicians throughout the world to learn, teach, present, perform research, and practice better medicine, while connecting industry to a global community of clinicians and researchers. Get started with PathPresenter, for free, at https://pathpresenter.net/. Our new ClinPX TM clinical enterprise platform helps hospitals and labs expand the reach of their clinical consultation (2 nd opinion) services globally, increase their efficiency, and optimize the user experience for both consulting pathologists and client pathologists. Through deep integration with the institution’s existing laboratory information system (LIS), consulting pathologists can receive, view, and sign out cases uploaded from around the world directly in the LIS. ClinPX allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists in addition to bidirectional communication channels for ordering stains and recuts. Further, it enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. Through a robust API, ClinPX integrates with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.net

April 13, 2022 11:00 AM Eastern Daylight Time

Metabolic fitness platform Ultrahuman acquires consumer-focused wearable company LazyCo

Ultrahuman

Ultrahuman, the world’s most advanced metabolic fitness platform, has today announced the acquisition of consumer-focused wearable company LazyCo famed for creating the Aina ring wearable. LazyCo will integrate with Ultrahuman’s global in-house hardware development team as they seek opportunities to enhance the user experience and help improve global metabolic health standards. Ultrahuman will leverage the LazyCo team’s expertise to generate deeper metabolic insights and better overall health insights for consumers. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome diversity, stress levels, time of the day, food ingredient quality, etc. With this acquisition, the idea would be to expand the set of real-time biomarkers that could provide unique health insights upon correlation. LazyCo was founded by engineers turned product designers, Apoorv Shankar and Yogansh Namdeo in 2017. The company focused on building hardware products that made daily life easier. One of the notable products included the Aina Ring - an AI-powered smart ring designed to predict and automate daily tasks without the need to take the phone out of the pocket. Digital tasks such as booking cabs, controlling smart home devices, activating SOS alerts, and taking phone calls, were 7x faster and easier through the ring. LazyCo completed a successful Kickstarter campaign in 2019 and won several design and startup awards from the likes of Alibaba and Qualcomm. “Ultrahuman’s vision of making health more personalized and impactful for people syncs with LazyCo’s vision of building products that solve problems for people in the most effortless ways. Together, we can create a deeper impact on the overall health of the world,” said Apoorv Shankar, Co-Founder and CEO, LazyCo. Ultrahuman launched with a wearable (the “Ultrahuman M1”) - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day. It triggers timely nudges to the user such as alerts to a high blood glucose event and suggestions to take a walk for optimizing their glucose levels. “We want to make it easy to get healthy. At Ultrahuman, we’re deep believers in passive personalized health, specifically in a health platform that requires very minimal effort from a user’s perspective. This perfectly aligns with the philosophy of LazyCo.” said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). There, he observed athletes train smartly via the usage of data, recovery tools and protocols. He got together with Vatsal and they came up with a vision for Ultrahuman where they can make the journey of fitness for people more personalized and impactful. Ultrahuman is a venture-backed startup that has raised $25m to date. Their investors include Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of marquee founders and angel investors including Tiger Global’s Scott Schleifer. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

April 12, 2022 09:00 AM Eastern Daylight Time

Image

Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State University’s College of Veterinary Medicine to test and evaluate its saponin-based adjuvants in several of the university’s veterinary vaccines. Among the most highly regarded universities in the nation for veterinary vaccine science, K-State is home to the Biosecurity Research Institute, a world-renowned high-security containment facility. The Master Agreement will benefit Q-VANT and the university. The first project under the agreement will compare Q-VANT’s 100% sustainable saponin-based adjuvants to other known adjuvants utilizing K-State’s subunit classic swine fever (CSF) vaccine. This study will further the university’s instructional and research project objectives while advancing its vaccine development program. For Q-VANT, the study will serve to validate the safety and efficacy of the company’s Quillaja saponin-based adjuvants. “We’re excited to be working with Kansas State University and are looking forward to demonstrating the safety and efficacy of our adjuvants for widespread use in the global veterinary pharmaceutical market. The CSF field trial is the first of many we hope to perform with K-State using our 100% sustainable saponin-based adjuvants,” said Q-VANT’s Chief Commercial Officer, Juan Jose Allbarran. The CSF vaccine was developed by K-State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the U.S.-China/Asia Center for Animal Health, where he and his team are working on novel vaccine and diagnostic strategies that are aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF) and other emerging viral diseases of swine. “This partnership is an exciting opportunity for all involved,” said Dr. Shi. “Our students will have the opportunity to take part in a research project that has the potential to have a major positive impact globally in animal vaccine development and usage.” About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times - enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 q-vant@svmpr.com Company Website https://q-vant.com/

April 12, 2022 08:00 AM Eastern Daylight Time

CORRECTING and REPLACING Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

In the last sentence boilerplate of release dated April 11, 2022, "multiple accolated and awards" corrected to read "multiple awards". The updated release reads: Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 12:24 PM Eastern Daylight Time

Cannabis Education Event to Inform and Empower Consumers

MCR Labs

Local cannabis testing laboratory MCR Labs is hosting a consumer education event aimed at empowering consumers with the knowledge they need to make informed decisions about their cannabis purchases and consumption choices. The event, which is free and open to the public, will feature a presentation by MCR’s Vice President of Scientific Development Scott Churchill and InhaleMD’s President & CEO Dr. Jordan Tishler. Dr. Tishler is a Cannabinoid Specialist. “There is a lot of speculation out there on terms like ‘Total Active Cannabinoids’ and how factors like shelf life stability affect product quality,” said Churchill. “Our goal here is to help consumers develop a deeper understanding of cannabis so they can choose the right product for themselves.” MCR Labs provides analytical cannabis testing services to cultivators and product manufacturers. The data produced by these services, such as cannabinoid content, is often advertised on product labels. “It’s really important that patients understand how compounds like cannabinoids interact with their bodies,” said Dr. Tishler. “This can help them understand their medicine and work with their healthcare professionals to achieve optimal treatment.” Through his training in Internal Medicine and years of practice as an Emergency Physician, Dr. Tishler brings his knowledge, reason, and caring to patients at inhale MD, and through his advocacy work at the local and national levels. “What’s In Your Weed: The Educated Consumer” will be held this Thursday, April 14 from 6 to 8 p.m. at District Hall in Boston. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

April 11, 2022 11:08 AM Eastern Daylight Time

1 ... 213 214 215 216 217 ... 290